Provider review
Clume Health Review: A Peptide Program Named for Nothing, Priced at Two Numbers
Clume Health's peptide program is called Molecular Cellular Optimization, which sounds like a medical category and is not one. Behind the name are NAD+ and sermorelin, sold together under a single seven-word claim, at a price the homepage states 57 dollars below anything actually on sale. The card you click to buy it spells the drug "Semorlin".
Names four pharmacies and no clinician, invents a medical-sounding category for two untested peptides, and advertises the program at a price it does not sell.
Worth trusting if
- You want the dispensing pharmacies named, with addresses and telephone numbers, which four of them are
- You want a LegitScript seal that at least resolves and points at the right domain
- You are content to commit to twelve weeks, because that is the only way this program is sold
Be skeptical if
- You are budgeting from the homepage, because neither headline price matches anything on sale
- You want a month-to-month peptide option, because none is published
- You expect the page selling a drug to spell it correctly
Compounded only
No trial for this use
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.clumehealth.com. A link is not a recommendation to take anything.
Provenance
What Clume Health actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- MCO — Molecular Cellular Optimization (oral, nasal or injectable) — $216 a month, available only on a 12-week plan — no month-to-month rate is published for this program. The homepage advertises it at $159.
- MCO — Molecular Cellular Optimization (oral, nasal or injectable) — Sold as one program with sermorelin, so no NAD+-only price exists.
- Microdose/Maintain — From $219 a month, or $200 on a 12-week plan. The homepage advertises the GLP-1 programs from $199, below both.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
0
Molecules with human evidence
For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to Clume Health.
0
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Clume Health’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
MCO — Molecular Cellular Optimization (oral, nasal or injectable)Sermorelin · Compounded (503A)No trial supports this claim
“MCO — Molecular Cellular Optimization. NAD+/Semorlin starting $216/month on a 12-week plan. Oral. Nasal. Injectable. Supports cellular health & longevity.”
Read on the Clume Health site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests cellular health, longevity, energy or recovery in healthy adults. A parallel ClinicalTrials.gov search returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants. No trial of any kind has tested sermorelin given nasally or by mouth.
Start with the spelling, because it is on the card a buyer clicks to begin: the drug is sermorelin, and the page calls it "Semorlin". Then the substance. Nineteen randomized sermorelin trials exist, they measured growth hormone release, and none of them measured cellular health or longevity. The routes compound the problem — this is offered orally and nasally as well as by injection, and every one of those nineteen trials used an injection. A peptide given by mouth faces the same absorption problem that forced the one approved oral GLP-1 to carry a dedicated enhancer, and nothing equivalent has been published here.1
MCO — Molecular Cellular Optimization (oral, nasal or injectable)NAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“Molecular & Cellular Optimization (MCO) — Advanced therapies designed to support energy, recovery, and long-term health at a cellular level.”
Read on the Clume Health site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. There is no completed randomized trial of oral NAD+ itself and none of a nasal formulation. The substantial human literature concerns ORAL PRECURSORS — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules, and results from them do not transfer to NAD+ given by any of these three routes.
"Advanced therapies designed to support energy, recovery, and long-term health at a cellular level" is four claims and a modifier, and the modifier is doing most of the work. "Advanced" is not a property of a molecule. Underneath it, no completed randomized trial of NAD+ exists for any of the three routes on offer here, and the large literature people reach for concerns precursors taken by mouth, which are different molecules. The program's own name is the deepest part of the problem: "Molecular Cellular Optimization" is a coinage, not a medical category, and it lets a buyer feel oriented without being told anything.2
Microdose/MaintainSemaglutide · Compounded (503A)No trial supports this claim
“Microdosing Programs — Support mental clarity, focus, and overall well-being through carefully guided protocols.”
Read on the Clume Health site, September 2026
No trial for this use
What the trials show for Semaglutide
As of September 2026, no completed randomized trial has tested a microdosed GLP-1 for cognition. Searched on ClinicalTrials.gov with no status filter, "microdose semaglutide" and "low-dose semaglutide cognition" each return zero studies, while a bare "semaglutide" search in the same pass returns hundreds — so the zeros are a finding rather than a broken search. The semaglutide trial program measured body weight, glycemic control and cardiovascular events at therapeutic doses. Mental clarity and focus were not endpoints in any of it, at any dose.
This is a cognitive claim attached to a weight-loss drug at a dose below the one that was studied, and it is worth separating the two problems. The dose: microdosing is not a tested regimen for semaglutide or tirzepatide, so nothing is known about what it does. The outcome: mental clarity and focus were not measured in the trial program at any dose. Adding "through carefully guided protocols" describes the service around the drug, not evidence for it.3
Dispensing chain
Who actually fills your prescription
- RedRock Pharmacy
- Health Warehouse
- Precision Medicine
- Triad Rx
Read the full account
Clume names four pharmacies, with addresses and telephone numbers: RedRock Pharmacy in St. George, Utah; Health Warehouse in Florence, Kentucky; Precision Medicine in Bellmore, New York; and Triad Rx in Daphne, Alabama. Naming any pharmacy at all puts a seller ahead of most of this market, and naming four with contact details is more than most manage. Three things are missing around that disclosure. The site never states a compounding category for any of them, so a reader cannot tell which set of rules governs their preparation. It never says which pharmacy fills which program, so naming four does not tell you who made yours. And outside a generic definition in the Terms — "'Pharmacy' means any pharmacy (including compounding pharmacies)" — it never says the medication is compounded at all; a census over visible text and markup of all five site pages found no instance of either compounding category and no "compounded by". Separately, the same four pharmacies are named by several other sellers in this market. That is a shared vendor set and nothing more: it says nothing about who owns whom, and we draw no such conclusion. No clinician is named anywhere. The medical practice is identified only as "the OpenLoop Medical Practices" in the Terms, the privacy policy and the telehealth consent.
Read on the Clume Health site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published, and no compounding category is stated for any of the four named pharmacies. The LegitScript seal here is the best-formed one we found in this batch and it still cannot be taken all the way. Inspected on the live page: the seal id resolves while an invented id returns 403 through the same request, so the certificate is genuinely issued; its alt text names clumehealth.com, the live domain; and it links to LegitScript's own checker for that domain. That is everything a seal ought to have. The checker page is protected by a challenge that a reader has to pass, so the listing itself could not be read — which makes this issued and correctly attributed, but not independently confirmed end to end.
Read on the Clume Health site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
"Clume Health currently offers services in all 50 states plus Washington D.C. Some services may not be available in all 50 states or Washington D.C. Subject to change." No per-state list is published and no page says which services are limited where, so the qualifier cannot be acted on by a reader deciding whether their state is covered.
Read the full licensing claim
No clinician is named — no prescriber, no medical director, no advisory panel. The prescribing entity appears only as "the OpenLoop Medical Practices". The seller is North Atelier LLC, doing business as Clume Health, with governing law in Iowa and arbitration appearances in Polk County District Court, Des Moines; its own street address is published nowhere. Its refund policy promises a "24/7 patient support line", and no telephone number appears anywhere on the site — support is email only.
Read on the Clume Health site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Four dispensing pharmacies are named with street addresses and telephone numbers — more disclosure than most sellers in this market offer.
- Its LegitScript seal is well-formed: the certificate resolves, the alt text names the live domain, and it links to LegitScript's checker for that domain.
- Prices for all three programs are visible before any account or intake.
Show 3 more
- The prices on the program page are internally consistent, and the plan-length condition is stated on each card rather than buried.
- It identifies the medical practice partner by name in three separate legal documents.
- No FDA warning letter against Clume Health, North Atelier, OpenLoop or any of the four named pharmacies.
- The card selling sermorelin spells it "Semorlin".
- The homepage advertises the peptide program well below the only price it is actually sold at.
- The homepage GLP-1 figure is below both real program floors too.
Show 9 more
- Neither headline price resolves to a footnote — the page carries three asterisks and no note.
- "Molecular Cellular Optimization" is a coinage rather than a medical category, and it is the only description the program has.
- The peptide claim is one sentence long and names no mechanism, no molecule behavior and no outcome that has been measured.
- No month-to-month price is published for the peptide program at all.
- The peptides are sold oral, nasal and injectable, and no completed randomized trial supports any of the three routes.
- The microdose program claims mental clarity and focus, which were not endpoints in the GLP-1 trial program at any dose.
- No clinician is named, and the seller publishes no street address of its own.
- The refund policy promises a 24/7 patient support line while no telephone number appears anywhere on the site.
- The compounding category of the four named pharmacies is never stated, and the site never says the medication is compounded.
Verdict
The bottom line
Clume discloses more about its pharmacies than most of this market and less about everything else. Its peptide program has a name that sounds like a diagnosis, a claim seven words long, two routes nobody has tested, one price that only exists on a twelve-week commitment, and another price on the homepage that is not for sale. Before you buy, get the month-to-month rate in writing if you want one, and note that the card taking your money misspells the drug it is selling.
Opens www.clumehealth.com. A link is not a recommendation to take anything.
A category that does not exist
Clume's peptide program is called Molecular Cellular Optimization, abbreviated MCO.
That is not a medical category. It is a coinage, and it is doing a specific job: it lets a buyer feel oriented — this is the cellular one — without being told what the products are or what they do.
Here is the entire program card, read live from the page you click to buy:
MCO · Molecular Cellular Optimization
NAD+/Semorlin starting $216/month on a 12-week plan
Oral · Nasal · Injectable
"Supports cellular health & longevity."
Seven words of claim. No mechanism, no molecule behavior, no outcome anyone has measured.
And the drug is misspelled. It is sermorelin. Not in a blog post — on the purchase card.
Full analysis — 4 more sectionsThe price on the homepage is not for sale · Three routes, no trials · The microdose program's cognitive claim · What Clume does better than most
The price on the homepage is not for sale
The homepage:
"Molecular Cellular Optimization programs starting at *$159/month."
The program page: $216/month, on a 12-week plan. There is no month-to-month MCO rate published anywhere.
The GLP-1 hero has the same shape — advertised from $199, with real floors of $259 and $219.
Both figures carry an asterisk. We counted the asterisks on the live page: there are exactly three, the two price prefixes and a decorative one in "The Clume Experience*". There is no footnote.
Three routes, no trials
MCO is offered oral, nasal, or injectable.
Every one of the nineteen randomized sermorelin trials used an injection. 1 For NAD+ there is no completed randomized trial by any route at all — and the large body of research people point to is about precursors taken by mouth, nicotinamide riboside and nicotinamide mononucleotide, which are different molecules. 2
A peptide swallowed or sprayed faces the same absorption problem that forced the one approved oral GLP-1 to carry a dedicated absorption enhancer and run its own phase 3 program. Nothing equivalent has been published for either of these.
The microdose program's cognitive claim
Separately, on the homepage:
"Microdosing Programs — Support mental clarity, focus, and overall well-being through carefully guided protocols."
Two problems stacked. Microdosing is not a tested regimen for semaglutide or tirzepatide, so nothing is known about what these doses do. And mental clarity and focus were not endpoints in the GLP-1 trial program at any dose — those trials measured weight, glycemic control and cardiovascular events. 3
What Clume does better than most
It names its pharmacies. Four of them, with street addresses and telephone numbers: RedRock Pharmacy, Health Warehouse, Precision Medicine and Triad Rx. Most sellers in this market name none.
Its LegitScript seal is the best-formed one in this batch — the certificate resolves where an invented one returns an error, the alt text names the live domain, and it links to LegitScript's checker for that domain.
The gaps sit right beside those strengths. The site never states a compounding category for any of the four pharmacies, never says which one fills which program, and — outside a generic definition in the Terms — never says the medication is compounded at all. And no clinician is named anywhere: the prescribing side appears only as "the OpenLoop Medical Practices".
Questions
Frequently asked questions
What is in the MCO program?
NAD+ and sermorelin, offered as an oral, nasal or injectable formulation. The card writes the second one as "Semorlin". "Molecular Cellular Optimization" is the seller's own coinage rather than a medical category, and it is the only description the program carries beyond the sentence "Supports cellular health & longevity."
Why does the homepage price differ from the program price?
We do not know, and the site does not explain it. The homepage advertises the peptide program from one figure; the program page sells it at a higher one, and only on a twelve-week plan. Both homepage figures carry an asterisk, and the page contains no footnote — we counted three asterisks on the live page and none resolves to a note.
Can I buy the peptide program month to month?
Not at any published price. The only figure on the card is conditioned on a 12-week plan, and no month-to-month MCO rate appears anywhere on the site. If you want one, get it in writing before you start.
Is nasal or oral sermorelin as good as injected?
Nobody has published an answer. All nineteen randomized sermorelin trials used an injection, and none tested an oral or nasal route. A peptide taken by mouth faces the absorption problem that forced the one approved oral GLP-1 to carry a dedicated enhancer and run its own phase 3 program; nothing equivalent exists here.
Will microdosing help my focus?
No trial supports that. Microdosing is not a tested regimen for semaglutide or tirzepatide, and mental clarity and focus were not endpoints anywhere in the GLP-1 trial program at any dose — those trials measured weight, glycemic control and cardiovascular events.
Which pharmacy will fill my prescription?
The site names four — RedRock Pharmacy, Health Warehouse, Precision Medicine and Triad Rx, each with an address and a telephone number — but never says which one fills which program. It also never states their compounding category, and outside a generic definition in the Terms it never says the medication is compounded.
Does Clume hold an FDA warning letter?
No FDA warning letter. We searched FDA's warning-letter database for "Clume Health", "North Atelier", "OpenLoop" and all four named pharmacies, and every one came back empty. Searching the shorter string "Clume" does return a 2023 letter — to OcluMed LLC of Fort Washington, Pennsylvania. We opened and read that letter before ruling it out: it matches neither the company, the domain nor the address, and has nothing to do with Clume Health.
Glossary
Key terms
Show definitions
- Microdosing
- Taking a dose below the range a drug was studied at. For GLP-1 medicines it is not a tested regimen, so what a microdose does — including whether it does anything — has not been measured in a trial.
- NAD+ precursor
- A different molecule the body converts into NAD+, such as nicotinamide riboside or nicotinamide mononucleotide. Most of the human research cited for NAD+ products was done on precursors taken by mouth and does not transfer to NAD+ given directly.
Compare
Others selling what Clume Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Clume Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005, all using an injected route; ClinicalTrials.gov intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans; no completed randomized trial of oral or nasal NAD+. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov, no status filter: "microdose semaglutide" 0 studies, "low-dose semaglutide cognition" 0; control "semaglutide" returns hundreds in the same pass. The semaglutide program's endpoints were body weight, glycemic control and cardiovascular events. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=semaglutide
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.